NervGen Pharma Strengthens Leadership Team with Appointments of Shamim Ruff and Christine McSherry

NervGen Pharma has appointed Shamim Ruff as Chief Regulatory Affairs Officer and Christine McSherry as SVP, Patient Advocacy and Clinical Affairs. Shamim brings over 30 years of regulatory expertise, while Christine has a unique combination of patient advocacy and clinical development experience. They will support the advancement of NVG-291 toward potential approval as the first pharmacologic treatment for spinal cord injury.